J Triscari
Overview
Explore the profile of J Triscari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
493
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jimenez J, Rosen J, Pirags V, Massaad R, Hanson M, Brudi P, et al.
Diabetes Obes Metab
. 2013 Jan;
15(6):513-22.
PMID: 23279632
Aims: The objective was to assess the consistency of effect of switching to ezetimibe/simvastatin 10/20 mg versus doubling the baseline statin dose (to simvastatin 40 mg or atorvastatin 20 mg)...
2.
Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves R
Am J Hypertens
. 1999 Sep;
12(8 Pt 1):797-805.
PMID: 10480473
The purpose of this study was to assess the safety and antihypertensive dose-response effects of irbesartan and hydrochlorothiazide (HCTZ) in patients with mild-to-moderate hypertension. After a 4- to 5-week single-blind...
3.
Oparil S, Guthrie R, Lewin A, Marbury T, Reilly K, Triscari J, et al.
Clin Ther
. 1998 Jul;
20(3):398-409.
PMID: 9663357
This multicenter, randomized, double-masked, elective-titration study was designed to compare the effectiveness, safety, and tolerability of irbesartan and losartan, two angiotensin II subtype AT1-receptor blockers, in the treatment of patients...
4.
Triscari J, ODonnell D, ZINNY M, Pan H
J Clin Pharmacol
. 1995 Feb;
35(2):142-4.
PMID: 7751423
The bioavailability of pravastatin, a hypocholesterolmic agent, may be enhanced by decreasing its exposure to stomach contents, where it may be converted nonenzymatically to a relatively inactive metabolite. The pharmacokinetics...
5.
Triscari J, Markowitz J, McGovern M
Clin Neuropharmacol
. 1993 Dec;
16(6):559-60.
PMID: 9377592
No abstract available.
6.
Triscari J, Swanson B, Willard D, Cohen A, DeVault A, Pan H
Br J Clin Pharmacol
. 1993 Sep;
36(3):263-5.
PMID: 9114914
Pravastatin is an HMG CoA reductase inhibitor used in the treatment of hypercholesterolaemia. The steady state pharmacokinetics of pravastatin (20 mg) and digoxin (0.2 mg) were evaluated in 18 healthy...
7.
Tilley J, Danho W, Madison V, Fry D, Swistok J, Makofske R, et al.
J Med Chem
. 1992 Oct;
35(22):4249-52.
PMID: 1433225
No abstract available.
8.
Tilley J, Danho W, Shiuey S, Kulesha I, Swistok J, Makofske R, et al.
J Med Chem
. 1992 Oct;
35(21):3774-83.
PMID: 1433191
A series of analogs of Ac-CCK-7 [Ac-Tyr(SO3H)-Met28-Gly29-Trp-Met-Asp- Phe-NH2, (1)] were prepared in which the Met28-Gly29 dipeptide was replaced by omega-aminoalkanoic acids. Compounds were assessed in binding assays using homogenated rat...
9.
Danho W, Tilley J, Shiuey S, Kulesha I, Swistok J, Makofske R, et al.
Int J Pept Protein Res
. 1992 Apr;
39(4):337-47.
PMID: 1428523
Cholecystokinin represents a family of gut hormones which among other activities, have been proposed to participate in satiety signaling. Ac-CCK-7[Ac-Tyr(SO3H)-Met-Gly-Trp30-Met-Asp-Phe-NH2 (2)] possesses the full spectrum of activity and potency of...
10.
Halstenson C, Triscari J, DeVault A, Shapiro B, KEANE W, Pan H
J Clin Pharmacol
. 1992 Feb;
32(2):124-32.
PMID: 1613121
The disposition of a single 20-mg oral dose of pravastatin was assessed in subjects with various degrees of renal function. Sixteen subjects (13 males, 3 females) with creatinine clearance values...